Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Prothena Corporation plc
PRTA | US
9.19
USD-0.40
-4.17%
PRTA | US
About Prothena Corporation plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
9.19
Open
9.59
High
9.59
Low
9.12
Prothena Corporation plc a late-stage clinical company focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab a humanized monoclonal antibody which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005 which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123 a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license development and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin Ireland.
View LessPRTA | US
Risk
59.9
Sharpe
1.94
Luna's Score
63/100
Recommendation
Hold
Luna says (PRTA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
57.7%1 month
59.9%3 months
50.6%6 months
49.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
64.10
Price to book
1.58
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
-3.58
Ent. to rev.
1.69
PEG
0.80
Other Fundamentals
EBITDA
-90.41M
MarketCap
494.24M
MarketCap(USD)
494.24M
Div. yield
-
Op. margin
44.22
Erngs. growth
-
Rev. growth
3.18K
Ret. on equity
-8.75
Short ratio
11.11
Short perc.
15.53
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.24
Range1M
2.78
Range3M
3.42
Volumes: Market Activity
Rel. volume
0.79
Price X volume
4.03M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.58 | - | Cheaper |
| Ent. to Revenue | 1.69 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.58 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 50.62 | - | Lower Risk |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 494.24M | - | Emerging |
